Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
World game at war: why some European nations have threatened a World Cup boycott 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
BUENA, N.J., May 07, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, initially announced the Company would hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1st quarter 2018 financial results and business update. This call will be rescheduled for 8:30am ET on Tuesday, May 8, 2018.
The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to join the Teligent, Inc. call.
This call is available via webcast and can be accessed in the Investor Relations Section of Teligent, Inc.'s website at www.teligent.com.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
